Komici et al. investigated the potential of Gal-3 to serve as a biomarker of frailty in elderly HF patients with reduced ejection fraction, showing that serum Gal-3 levels were significantly associated with Clinical Frailty Scale and, furthermore, adding serum Gal-3 to the prognostic model improved the net clinical benefit [78]. Here, LGALS3 is linked to hydrops fetalis.